The state of California currently has 6 active clinical trials seeking participants for Primary Biliary Cholangitis research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Recruiting
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: Southern California Research Center, Coronado, California +2 locations
Conditions: Primary Biliary Cholangitis, PBC
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Recruiting
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/08/2024
Locations: Om Research LLC, Lancaster, California +5 locations
Conditions: Primary Biliary Cholangitis
IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Recruiting
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/08/2024
Locations: California Liver Reasearch Institute, Pasadena, California +4 locations
Conditions: Primary Biliary Cholangitis
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
Recruiting
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC). Participants will also have inadequate response or intolerance to ursodeoxycholic acid (UDCA) a drug used to treat PBC. PBC is a disease that progresses slowly. It causes damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many people with PBC may re... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: GastroIntestinal BioSciences, Los Angeles, California
Conditions: Primary Biliary Cholangitis (PBC)
An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Recruiting
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/26/2024
Locations: University of California Davis Medical Center, Sacramento, California
Conditions: Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis
Recruiting
Saroglitazar Magnesium 1 mg and 2 mg tablets for treatment of subjects with Primary Biliary Cholangitis (PBC)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
12/30/2023
Locations: Zydus US013, Los Angeles, California +2 locations
Conditions: Primary Biliary Cholangitis